TG Therapeutics Investigational Trial Site

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis	Relapsing Multiple Sclerosis (RMS)	Active, not recruiting	Phase 3	2026-09-23		NCT04130997
A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS)	CNS demyelinating autoimmune disease, autoimmune disease, autoimmune disorder of the nervous system, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder	Recruiting	Phase 2	2026-09-21		NCT07503873

Clinical trials